INCY insider filings
INCYTE CORP — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-18. Screen INCY transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 13 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 17 legs across 7 filings by 4 insiders — 280,575 shares, $33,285,604 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 65.
- Largest priced transaction: sale of 73,969 shares @ $119.12 ($8,811,010) by Stein Steven H, filed 2026-11-10.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Stein Steven H — CMO & Head of Late-Stage Dev. | 2 | — | 6 legs · 240,769 sh · $28,506,009 | 34 |
| CAGNONI PABLO J — President, Global Head of R&D | 3 | — | 5 legs · 28,502 sh · $3,414,997 | 24 |
| Heeson Lee — EVP, Head of Incyte Intl | 2 | — | 5 legs · 10,694 sh · $1,292,032 | 1 |
| Tray Thomas — Principal Accounting Officer | 1 | — | 1 leg · 610 sh · $72,566 | — |
| BAKER BROS. ADVISORS LP — Director, 10% owner & 667, L.P. — Director, 10% owner & Baker Bros. Advisors (GP) LLC — Director, 10% owner & Baker Brothers Life Sciences LP — Director, 10% owner & BAKER FELIX — Director, 10% owner & BAKER JULIAN — Director, 10% owner | 1 | — | — | 2 |
| Basi Ramitpal K — EVP, Human Resources | 1 | — | — | 1 |
| Clancy Paul J — Director | 1 | — | — | 1 |
| Gardner David H — EVP, Chief Strategy Officer | 1 | — | — | 1 |
| HARRIGAN EDMUND — Director | 1 | — | — | 1 |
Recent insider filings — INCYTE CORP
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-18 | 4 | CAGNONI PABLO J — President, Global Head of R&D | Option exercise (M): 455 @ $61.18 · Option exercise (M): 422 @ $61.76 · Option exercise (M): 926 @ $64.25 · Option exercise (M): 839 @ $71.93 · Sale (S): 877 @ $121.98 · Sale (S): 1,765 @ $120.46 · +4 more | EDGAR |
| 2026-11-18 | 4 | Stein Steven H — CMO & Head of Late-Stage Dev. | Option exercise (M): 576 @ $68.25 · Sale (S): 576 @ $121.98 · Option exercise (M): 576 (derivative) @ $0 | EDGAR |
| 2026-11-17 | 4 | Heeson Lee — EVP, Head of Incyte Intl | Sale (S): 1,471 @ $121.89 · Sale (S): 2,200 @ $120.44 · Sale (S): 874 @ $121.16 · Sale (S): 3,700 @ $120.33 · Sale (S): 2,449 @ $121.13 | EDGAR |
| 2026-11-10 | 4 | Stein Steven H — CMO & Head of Late-Stage Dev. | Option exercise (M): 8,539 @ $68.62 · Option exercise (M): 12,335 @ $72.27 · Option exercise (M): 16,428 @ $80.50 · Option exercise (M): 15,054 @ $74.78 · Option exercise (M): 23,526 @ $77.67 · Option exercise (M): 18,331 @ $61.76 · +31 more | EDGAR |
| 2026-11-05 | 4 | Tray Thomas — Principal Accounting Officer | Sale (S): 610 @ $118.96 | EDGAR |
| 2026-10-19 | 4 | CAGNONI PABLO J — President, Global Head of R&D | Option exercise (M): 839 @ $71.93 · Option exercise (M): 423 @ $61.76 · Option exercise (M): 455 @ $61.18 · Option exercise (M): 925 @ $64.25 · Sale (S): 2,642 @ $112.71 · Option exercise (M): 839 (derivative) @ $0 · +3 more | EDGAR |
| 2026-10-05 | 4 | Heeson Lee — EVP, Head of Incyte Intl | Tax withholding (F): 463 @ $117.14 | EDGAR |
| 2026-10-02 | 4 | BAKER BROS. ADVISORS LP — Director, 10% owner 667, L.P. — Director, 10% owner Baker Bros. Advisors (GP) LLC — Director, 10% owner Baker Brothers Life Sciences LP — Director, 10% owner BAKER FELIX — Director, 10% owner BAKER JULIAN — Director, 10% owner | Grant/award (A): 322 @ $0 · Grant/award (A): 322 @ $0 | EDGAR |
| 2026-10-02 | 4 | HARRIGAN EDMUND — Director | Grant/award (A): 206 @ $121.35 | EDGAR |
| 2026-10-02 | 4 | Clancy Paul J — Director | Grant/award (A): 203 @ $121.35 | EDGAR |
| 2026-09-24 | 4 | Gardner David H — EVP, Chief Strategy Officer | Tax withholding (F): 920 @ $126.93 | EDGAR |
| 2026-09-17 | 4 | CAGNONI PABLO J — President, Global Head of R&D | Option exercise (M): 2,957 @ $61.76 · Option exercise (M): 4,551 @ $61.18 · Option exercise (M): 6,477 @ $64.25 · Option exercise (M): 9,233 @ $71.93 · Sale (S): 9,233 @ $120.50 · Sale (S): 13,985 @ $120.49 · +4 more | EDGAR |
| 2026-08-27 | 4 | Basi Ramitpal K — EVP, Human Resources | Tax withholding (F): 504 @ $129.72 | EDGAR |
| 2026-08-20 | 4 | CAGNONI PABLO J — President, Global Head of R&D | Sale (S): 10,801 @ $125.56 | EDGAR |
| 2026-08-14 | 4 | CAGNONI PABLO J — President, Global Head of R&D | Sale (S): 10,803 @ $120.04 | EDGAR |
| 2026-08-07 | 4 | Mayes Patrick A — EVP & Chief Scientific Officer | Option exercise (M): 2,207 @ $106.47 · Sale (S): 2,207 @ $123.99 · Option exercise (M): 2,207 (derivative) @ $0 | EDGAR |
| 2026-08-07 | 4 | CAGNONI PABLO J — President, Global Head of R&D | Sale (S): 10,640 @ $122.69 | EDGAR |
| 2026-08-04 | 4 | CAGNONI PABLO J — President, Global Head of R&D | Sale (S): 15,888 @ $119.70 | EDGAR |
| 2026-08-04 | 4 | Mayes Patrick A — EVP & Chief Scientific Officer | Option exercise (M): 2,918 @ $61.18 · Option exercise (M): 2,284 @ $64.25 · Option exercise (M): 2,709 @ $61.76 · Option exercise (M): 3,148 @ $68.62 · Option exercise (M): 2,072 @ $71.93 · Option exercise (M): 9,459 @ $72.27 · +38 more | EDGAR |
| 2026-07-27 | 4 | Heeson Lee — EVP, Head of Incyte Intl | Grant/award (A): 15,423 (derivative) @ $0 · Grant/award (A): 13,498 (derivative) @ $0 | EDGAR |
| 2026-07-27 | 4 | Morrissey Michael James — EVP, Head of Tech. Operations | Grant/award (A): 6,426 (derivative) @ $0 · Grant/award (A): 8,999 (derivative) @ $0 | EDGAR |
| 2026-07-20 | 4 | Hoffman Richard A. — EVP & General Counsel | Grant/award (A): 7,395 @ $0 · Grant/award (A): 18,487 (derivative) @ $0 · Grant/award (A): 31,923 (derivative) @ $0 | EDGAR |
| 2026-07-20 | 4 | Gardner David H — EVP, Chief Strategy Officer | Grant/award (A): 7,395 @ $0 · Grant/award (A): 18,487 (derivative) @ $0 · Grant/award (A): 31,923 (derivative) @ $0 | EDGAR |
| 2026-07-20 | 4 | Basi Ramitpal K — EVP, Human Resources | Grant/award (A): 4,991 @ $0 · Grant/award (A): 12,479 (derivative) @ $0 · Grant/award (A): 21,548 (derivative) @ $0 | EDGAR |
| 2026-07-20 | 4 | Mayes Patrick A — EVP & Chief Scientific Officer | Grant/award (A): 5,916 @ $0 · Grant/award (A): 14,790 (derivative) @ $0 · Grant/award (A): 25,538 (derivative) @ $0 | EDGAR |
| 2026-07-20 | 4 | Issa Mohamed Khairie — EVP, Head of U.S. Commercial | Sale (S): 1,093 @ $115.01 · Grant/award (A): 7,857 @ $0 · Grant/award (A): 19,643 (derivative) @ $0 · Grant/award (A): 33,918 (derivative) @ $0 | EDGAR |
| 2026-07-20 | 4 | Tray Thomas — Principal Accounting Officer | Grant/award (A): 2,834 @ $0 · Grant/award (A): 4,079 (derivative) @ $0 | EDGAR |
| 2026-07-20 | 4 | Stein Steven H — CMO & Head of Late-Stage Dev. | Sale (S): 1,877 @ $114.73 · Grant/award (A): 9,798 @ $0 · Grant/award (A): 24,496 (derivative) @ $0 · Grant/award (A): 42,298 (derivative) @ $0 | EDGAR |
| 2026-07-20 | 4 | Meury William — Chief Executive Officer, Director | Grant/award (A): 26,807 @ $0 · Grant/award (A): 80,421 (derivative) @ $0 · Grant/award (A): 77,148 (derivative) @ $0 | EDGAR |
| 2026-07-20 | 4 | CAGNONI PABLO J — President, Global Head of R&D | Grant/award (A): 13,403 @ $0 · Grant/award (A): 33,508 (derivative) @ $0 · Grant/award (A): 57,861 (derivative) @ $0 | EDGAR |
| 2026-07-16 | 4 | Mayes Patrick A — EVP & Chief Scientific Officer | Tax withholding (F): 437 @ $114.88 · Tax withholding (F): 1,512 @ $115.09 | EDGAR |
| 2026-07-16 | 4 | Issa Mohamed Khairie — EVP, Head of U.S. Commercial | Tax withholding (F): 1,099 @ $115.09 | EDGAR |
| 2026-07-16 | 4 | Tray Thomas — Principal Accounting Officer | Tax withholding (F): 692 @ $114.88 · Tax withholding (F): 1,098 @ $115.09 | EDGAR |
| 2026-07-16 | 4 | Stein Steven H — CMO & Head of Late-Stage Dev. | Tax withholding (F): 21,830 @ $114.88 · Sale (S): 28,237 @ $113.05 · Tax withholding (F): 3,088 @ $115.09 | EDGAR |
| 2026-07-16 | 4 | CAGNONI PABLO J — President, Global Head of R&D | Tax withholding (F): 17,969 @ $114.88 · Tax withholding (F): 4,950 @ $115.09 | EDGAR |
| 2026-07-07 | 4 | Mayes Patrick A — EVP & Chief Scientific Officer | Tax withholding (F): 350 @ $116.86 | EDGAR |
| 2026-07-07 | 4 | Tray Thomas — Principal Accounting Officer | Tax withholding (F): 477 @ $116.86 | EDGAR |
| 2026-07-07 | 4 | Stein Steven H — CMO & Head of Late-Stage Dev. | Tax withholding (F): 2,177 @ $116.86 | EDGAR |
| 2026-07-07 | 4 | Meury William — Chief Executive Officer, Director | Tax withholding (F): 4,779 @ $116.86 | EDGAR |
| 2026-07-02 | 4 | Clancy Paul J — Director | Grant/award (A): 252 @ $113.36 | EDGAR |
| 2026-07-02 | 4 | HARRIGAN EDMUND — Director | Grant/award (A): 255 @ $113.36 | EDGAR |
| 2026-07-02 | 4 | BAKER BROS. ADVISORS LP — Director, 10% owner 667, L.P. — Director, 10% owner Baker Bros. Advisors (GP) LLC — Director, 10% owner Baker Brothers Life Sciences LP — Director, 10% owner BAKER FELIX — Director, 10% owner BAKER JULIAN — Director, 10% owner | Grant/award (A): 400 @ $0 · Grant/award (A): 400 @ $0 | EDGAR |
| 2026-06-10 | 4 | High Katherine A — Director | Grant/award (A): 1,642 @ $0 · Grant/award (A): 6,111 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Clancy Paul J — Director | Grant/award (A): 1,642 @ $0 · Grant/award (A): 6,111 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | FOUSE JACQUALYN A — Director | Grant/award (A): 1,642 @ $0 · Grant/award (A): 6,111 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | BIENAIME JEAN JACQUES — Director | Grant/award (A): 1,642 @ $0 · Grant/award (A): 6,111 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | BRAWLEY OTIS W — Director | Grant/award (A): 1,642 @ $0 · Grant/award (A): 6,111 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | HARRIGAN EDMUND — Director | Grant/award (A): 1,642 @ $0 · Grant/award (A): 6,111 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | BAKER BROS. ADVISORS LP — Director, 10% owner 667, L.P. — Director, 10% owner Baker Bros. Advisors (GP) LLC — Director, 10% owner Baker Brothers Life Sciences LP — Director, 10% owner BAKER FELIX — Director, 10% owner BAKER JULIAN — Director, 10% owner | Grant/award (A): 1,642 @ $0 · Grant/award (A): 1,642 @ $0 · Grant/award (A): 6,111 (derivative) @ $0 · Grant/award (A): 6,111 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Tray Thomas — Principal Accounting Officer | Option exercise (M): 2,639 @ $83.83 · Sale (S): 2,639 @ $100 · Option exercise (M): 2,639 (derivative) @ $0 | EDGAR |
Recent 8-K events — INCYTE CORP
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-13 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-10-29 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-31 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-07-28 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-06 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-22 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-06-09 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-06-08 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-04-28 | 8-K | 2.02 — Results of Operations and Financial Condition | EDGAR |
| 2026-03-30 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=INCY returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs